Cargando…

Combining SGLT2 Inhibition With a Thiazolidinedione Additively Attenuate the Very Early Phase of Diabetic Nephropathy Progression in Type 2 Diabetes Mellitus

Although both sodium glucose co-transporter 2 inhibition by dapagliflozin and thiazolidinedione, pioglitazone have glucose-lowering and anti-inflammatory effects, the therapeutic efficacy of their combination on diabetic nephropathy has not been investigated. 9-week-old male db/db mice were randomly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Eugene, Shin, Eugene, Kim, Gyuri, Lee, Ji-Yeon, Lee, Yong-ho, Lee, Byung-Wan, Kang, Eun Seok, Cha, Bong-Soo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6060671/ https://www.ncbi.nlm.nih.gov/pubmed/30072956 http://dx.doi.org/10.3389/fendo.2018.00412

Ejemplares similares

Differential Effects of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors on Insulin Resistance and β-Cell Function in Type 2 Diabetes Mellitus: A Propensity Score-Matched Analysis
por: Bae, Jaehyun, et al.
Publicado: (2018)

Beneficial Effects of Thiazolidinediones on Diabetic Nephropathy in OLETF Rats
por: Lee, Mi Young, et al.
Publicado: (2007)

Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus
por: Bae, Jaehyun, et al.
Publicado: (2021)

Effects of Omega-3 Fatty Acid Supplementation on Diabetic Nephropathy Progression in Patients with Diabetes and Hypertriglyceridemia
por: Han, Eugene, et al.
Publicado: (2016)

Relationship Between Circulating Netrin-1 Concentration, Impaired Fasting Glucose, and Newly Diagnosed Type 2 Diabetes
por: Yim, Jisook, et al.
Publicado: (2018)

Effects of Combination Therapy of Statin and Thiazolidinedione on Vascular Inflammation
por: Lee, Ji-Yeon, et al.
Publicado: (2018)

Association of ANGPTL8 and Resistin With Diabetic Nephropathy in Type 2 Diabetes Mellitus
por: Li, Mengni, et al.
Publicado: (2021)

Anthropometric Measures and Incident Diabetic Nephropathy in Participants With Type 2 Diabetes Mellitus
por: Hukportie, Daniel Nyarko, et al.
Publicado: (2021)

Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy
por: Kim, Youngsook, et al.
Publicado: (2022)

Therapeutic Targeting of SGLT2: A New Era in the Treatment of Diabetes and Diabetic Kidney Disease
por: Shaffner, James, et al.
Publicado: (2021)

Underutilization of Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Nephropathy Patients in Government-Run Hospitals in India
por: Maradia, Jay, et al.
Publicado: (2023)

Impaired ketogenesis is associated with metabolic-associated fatty liver disease in subjects with type 2 diabetes
por: Lee, Sejeong, et al.
Publicado: (2023)

Comparison between Atorvastatin and Rosuvastatin in Renal Function Decline among Patients with Diabetes
por: Han, Eugene, et al.
Publicado: (2017)

Age at Diagnosis and the Risk of Diabetic Nephropathy in Young Patients with Type 1 Diabetes Mellitus
por: Baek, Jong Ha, et al.
Publicado: (2021)

Dyslipidemia and serum cystatin C levels as biomarker of diabetic nephropathy in patients with type 2 diabetes mellitus
por: Dejenie, Tadesse Asmamaw, et al.
Publicado: (2023)

Clinical Management of Nonalcoholic Steatohepatitis (NASH) With the Use of Thiazolidinediones and the Additive Effect of Thiazolidinediones and a GLP-1 Agonist: Case Series
por: Rojas Ortiz, Valentina, et al.
Publicado: (2021)

Interaction Between Non-Insulin Glucose-Lowering Medication and Exercise in Type 2 Diabetes Mellitus – New Findings on SGLT2 Inhibitors
por: Brinkmann, Christian
Publicado: (2021)

Comparative Cardiovascular Outcomes of SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomized Controlled Trials
por: Jiang, Yu, et al.
Publicado: (2022)

Association Between Lipoprotein (A) and Diabetic Nephropathy in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis
por: Ren, Xiaoyan, et al.
Publicado: (2021)

Association Between Globulin and Diabetic Nephropathy in Type2 Diabetes Mellitus Patients: A Cross-Sectional Study
por: Wang, Jian, et al.
Publicado: (2022)

SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy
por: Kawanami, Daiji, et al.
Publicado: (2017)

SGLT2 inhibition to address the unmet needs in diabetic nephropathy
por: Barutta, Federica, et al.
Publicado: (2019)

Relationship Between SGLT-2i and Ocular Diseases in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials
por: Zhou, Bin, et al.
Publicado: (2022)

Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis
por: Li, Xuefeng, et al.
Publicado: (2022)

Comprehensive review of SGLT2 inhibitors’ efficacy through their diuretic mode of action in diabetic patients
por: Lam-Chung, Cesar Ernesto
Publicado: (2023)

Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial
por: Han, Eugene, et al.
Publicado: (2020)

Decreased Urine N6-methyladenosine level is closely associated with the presence of diabetic nephropathy in type 2 diabetes mellitus
por: Wan, Shu-jun, et al.
Publicado: (2022)

Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
por: Wei, Qiong, et al.
Publicado: (2021)

Type 2 Diabetes: Uses of thiazolidinediones and insulin
por: T. Bloomgarden, Zachary
Publicado: (2011)

High Expression of Complement Components in the Kidneys of Type 2 Diabetic Rats With Diabetic Nephropathy
por: Huang, Yinqiong, et al.
Publicado: (2019)

Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway
por: Lee, Ji-Yeon, et al.
Publicado: (2021)

Association between Non-Alcoholic Steatohepatitis and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus
por: Lee, Hokyou, et al.
Publicado: (2020)

SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
por: Shyangdan, Deepson S, et al.
Publicado: (2016)

Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes
por: Clar, Christine, et al.
Publicado: (2012)

New Diagnostic Model for the Differentiation of Diabetic Nephropathy From Non-Diabetic Nephropathy in Chinese Patients
por: Zhang, WeiGuang, et al.
Publicado: (2022)

Is thiazolidinediones use a factor in delaying the need for insulin therapy in type 2 patients with diabetes? A population-based cohort study
por: Carney, Greg A, et al.
Publicado: (2012)

Thiazolidinediones: the Forgotten Diabetes Medications
por: Lebovitz, Harold E.
Publicado: (2019)

Risk of Fracture with Thiazolidinediones: An Individual Patient Data Meta-Analysis
por: Bazelier, Marloes T., et al.
Publicado: (2013)

Zinc Alpha 2 Glycoprotein as an Early Biomarker of Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients
por: Sonkar, Satyendra K, et al.
Publicado: (2023)

Redefining the role of thiazolidinediones in the management of type 2 diabetes
por: Barnett, Anthony H
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_2cu8462llh25omdsst1fokpsfl